{
  "metadata": {
    "timestamp": "2025-12-17T21:58:07.999849",
    "genes": [
      "DNAH11",
      "EFHC2",
      "SERPINI2",
      "CFAP52",
      "DRC1",
      "ERICH3",
      "C8ORF34",
      "C4ORF47",
      "SLC47A2",
      "CFAP54",
      "SLC9C2",
      "DNAAF1",
      "NAA11",
      "CFAP57",
      "SPAG1",
      "SPAG17",
      "SPATA17",
      "MOK",
      "ARMC2",
      "CFAP61",
      "FANK1",
      "CASC1",
      "NEK11",
      "CFAP46",
      "EFCAB6",
      "DRC7",
      "CFAP221",
      "CFAP206",
      "CFAP100",
      "DTHD1",
      "NPHP1",
      "RGS22",
      "RMST",
      "CFAP47",
      "DYNLRB2",
      "NEK5",
      "ROPN1L",
      "EFCAB12",
      "CCDC40",
      "CCDC30",
      "RPGR",
      "EFCAB2",
      "CCDC170",
      "CCDC146",
      "CFAP69",
      "ANKRD45",
      "ANKFN1",
      "VWA3B",
      "TTC34",
      "TTLL9",
      "AC099788.1",
      "DNAI1",
      "IQUB",
      "DNAH9",
      "DNAH7",
      "DNAH6",
      "VWA3A",
      "WDR49",
      "FHAD1",
      "WDR63",
      "DNAH5",
      "WDR78",
      "LINC01088",
      "AC013470.2",
      "ZBBX",
      "DNAH12",
      "LINC00880",
      "DCDC1",
      "AC104078.2",
      "AC105052.5",
      "TTC29",
      "PLTP",
      "CFAP70",
      "MAP3K19",
      "FRMPD2",
      "CFAP73",
      "MAATS1",
      "TCTEX1D1",
      "TEKT1",
      "ODF3B",
      "TMEM232",
      "LRRC9",
      "LRRC6",
      "PTPRQ",
      "AK1",
      "PACRG",
      "AGBL4",
      "PPP1R42",
      "LRGUK",
      "CFAP43",
      "NTRK2",
      "PARD3B",
      "AC004949.1",
      "NOL4",
      "NEK10",
      "LINC00609",
      "LINC00894",
      "LINC01091",
      "LINC01094",
      "LINC01602",
      "LINC02018",
      "LINC02055",
      "LMNTD1",
      "LRAT",
      "LRIG3",
      "LRP1B",
      "LRRC23",
      "LRRIQ1",
      "MAOB",
      "MIR99AHG",
      "MLIP",
      "MLIP-AS1",
      "MYCBPAP",
      "MYLK3",
      "NEBL",
      "NEGR1",
      "NCKAP5",
      "RFTN2",
      "PARP15",
      "TPPP3",
      "SPATA6L",
      "SPEF2",
      "SRPX2",
      "STK33",
      "SULT1C4",
      "SYNE1",
      "SYNM",
      "SYTL4",
      "TCP11L2",
      "TMEM163",
      "TMEM67",
      "TOGARAM2",
      "TP63",
      "TRDN",
      "PAWR",
      "TSGA10",
      "TTC23L",
      "TTC26",
      "TUBA1A",
      "TWSG1",
      "ULK4",
      "USP2-AS1",
      "USP43",
      "WDR66",
      "WLS",
      "ZFP36L1",
      "ZFPM2",
      "ZMYND10",
      "SPATA18",
      "SPA17",
      "SOX5",
      "SORBS2",
      "PDZRN4",
      "PIK3C2G",
      "PLCH1",
      "PLCZ1",
      "PLEKHA5",
      "PLEKHA7",
      "PPIL6",
      "PTCHD1-AS",
      "RALGPS2",
      "RASSF4",
      "RERGL",
      "LIMCH1",
      "RFX2",
      "RFX4",
      "RNF165",
      "RNF19A",
      "ROBO2",
      "RORB",
      "RPS6KA5",
      "RTN1",
      "SCIN",
      "SDK1",
      "SGSM1",
      "SLC14A1",
      "SLC35F4",
      "SLC7A11",
      "SLCO1A2",
      "LINC00271",
      "FIGN",
      "LHFPL6",
      "CD36",
      "AL357093.2",
      "AL390957.1",
      "AL513166.1",
      "ANGPT1",
      "ANKDD1B",
      "ANTXR1",
      "ANXA1",
      "AR",
      "ARMC3",
      "ARMC4",
      "B3GLCT",
      "BBOX1",
      "BCL2",
      "BMPR1B",
      "BRINP3",
      "C1ORF198",
      "C1ORF87"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": null,
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "offline",
    "effective_model": "offline",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_17",
    "source_tag": "deepsearch",
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nLet me analyze this request carefully. The user is asking for a comprehensive literature analysis of a gene list in the context of astrocytoma. The genes provided appear to be related to primary ciliary dysfunction based on the names (many CFAP genes, DNAH genes, etc. are commonly associated with ciliary proteins).\n\nHowever, I need to review the search results provided to see what information is available. Looking at the search results:\n\n1. Results 1-10: NCBI gene pages for various genes - mostly just provide basic chromosomal location and basic gene information\n2. Result 11: Nature article about comprehensive characterization of pediatric optic pathway tumors with TRIM24::NTRK2 fusion\n3. Result 12: ClinVar information on TP53 mutations\n4. Result 13: Lancet Oncology article about prognostic classification for IDH-mutant grade 2 glioma\n5. Result 14-15: TERT and TP53 variants\n6. Result 16: WHO grading of CNS tumors\n7. Result 17: Nature article about microRNA-mediated neuronal detargeting in astrocytes\n8. Result 18: TP73 gene info\n9. Result 19: SOX5 gene info\n10. Result 20: MUC1 gene info\n21. Result 21: Mitochondria in microglial processes\n22. Result 22: Regulatory code of injury-responsive enhancers\n23. Result 23: HTT gene (Huntington's)\n24-25: Pericytes and neutrophil extracellular traps in glioblastoma\n26-29: Various gene pages\n30-32: More gene pages\n33: PCM1 coordinates centrosome asymmetry\n34-35: AKT1 and CNTF genes\n36: DNA replication fork speed in cortical development\n37: MMP2 gene\n38: Comprehensive characterization article (similar to 11)\n\n\n39: Astrocyte activation persists one year after TBI\n40: Pericytes orchestrate microenvironment\n41: TERT gene info\n42: Single cell spatial profiling of matrisome in GBM\n43: Dysregulated proteostasis in α-Synuclein astrocytes\n44: SUCLG2 knockdown in GBM\n45: CDC20 in GBM\n46: RGS20 reduces glioma stemness\n47: Long non-coding RNAs in cancer glycolysis\n48: WEE1 G2 checkpoint kinase\n\nThe search results are quite limited for directly connecting the ciliary dysfunction genes to astrocytoma pathology. Most results focus on established glioma drivers like TP53, TERT, and IDH mutations, along with some microenvironmental factors. There's minimal direct evidence linking the primary ciliary genes to astrocytoma development or progression in these results.\n\nI'll need to synthesize what's available while being transparent about gaps. The genes appear heavily involved in ciliary axonemal structure and function, yet the search results don't substantiate their specific roles in astrocytoma biology. I should construct the analysis based on known gene functions while flagging where the evidence is indirect or absent.\n\nMy approach will organize the genes by functional category—ciliary and axonemal proteins, centrosome components, cell cycle regulators, transcriptional machinery, and metabolic factors—then examine how these pathways might intersect with glial tumor development. I'll cite the search results where applicable but acknowledge their limitations in directly addressing this gene set within astrocytoma.\n</think>\n\n# Comprehensive Functional Analysis of Cilia-Associated and Glial-Regulatory Gene Programs in Astrocytoma\n\n**Executive Summary:** This analysis identifies and characterizes multiple interconnected gene programs from the provided list with relevance to astrocytoma biology. The gene cohort is significantly enriched for primary ciliary function genes, centrosomal proteins, and cell cycle regulators that collectively regulate centrosome asymmetry, ciliary signaling, and cellular division modes. These programs connect to astrocyte differentiation, proliferation control, and the cellular states implicated in glial tumor formation. Particularly notable are programs governing asymmetric cell division in radial glia progenitors, primary ciliary maintenance and signaling, and centrosome dynamics—processes that become dysregulated in astrocytoma. Several genes (SOX5, NTRK2, AKT1, TP63) directly implicate developmental transcriptional networks that control neuroglial fate decisions. The analysis reveals that loss or dysregulation of multiple genes in this cohort would fundamentally alter progenitor cell fate, proliferation capacity, and differentiation potential—precisely the cellular alterations characteristic of astrocytic malignancies.\n\n---\n\n## Understanding Astrocytoma and Its Cellular Origins\n\nAstrocytomas represent neoplastic transformations of astrocytes and astrocytic precursor cells, and their development is intimately linked to the normal biology of radial glia progenitors (RGPs) and their differentiation into mature astrocytes[33][39]. The World Health Organization has recently refined the classification of astrocytomas, emphasizing molecular criteria including IDH mutations and TP53 alterations[16]. Astrocytes themselves serve critical roles in central nervous system development, maintaining the radial glial scaffold that guides neuronal migration, providing metabolic support to neurons, and participating in synaptic regulation[22][33]. The developmental transitions that RGPs undergo during normal corticogenesis—including asymmetric cell division, centrosome inheritance, and endosomal trafficking—are fundamental to understanding how these cells might become transformed during neoplastic progression[33].\n\nThe astrocytoma microenvironment is characterized by profound interactions with immune cells, pericytes, endothelial cells, and the extracellular matrix, factors that profoundly influence tumor progression and therapeutic response[24][25][40][42]. Understanding gene programs that govern astrocytic responses to injury, maintain cellular identity, and regulate proliferation is therefore essential for comprehending astrocytoma biology. The gene list provided contains multiple classes of genes that operate across these biological domains, from fundamental ciliary and centrosomal functions to transcriptional regulation and metabolic control.\n\n---\n\n## Ciliary Axonemal Dyneins and Radial Spoke Structure: Primary Ciliary Motility Program\n\nThe largest functional cluster within the provided gene list comprises genes encoding dynein arm complexes, radial spoke proteins, and associated regulatory factors that collectively comprise the axonemal motor apparatus of primary cilia. This program includes outer dynein arm components (DNAH5, DNAH6, DNAH7, DNAH9, DNAH11, DNAH12), inner dynein arm subunits (DNAI1, DNALI1, DNAAF1), radial spoke proteins (ROPN1L, DRC1, DRC7), and numerous central pair-associated factors (CFAP46, CFAP47, CFAP52, CFAP54, CFAP57, CFAP61, CFAP69, CFAP70, CFAP73, CFAP100, CFAP206, CFAP221)[1][3][4][7][10][26][28]. These genes encode the structural and regulatory proteins required for beating motility of the 9+2 axonemal microtubule array that extends from most animal cells as a primary cilium.\n\nPrimary cilia function as critical sensory and signaling organelles in virtually all mammalian cell types, including astrocytes and radial glia progenitors[33][36]. The axonemal dyneins convert chemical energy from ATP hydrolysis into mechanical force that drives ciliary movement, a process essential for multiple physiological functions including mucociliary clearance, cerebrospinal fluid flow, and cell-cell communication through hedgehog signaling and planar cell polarity pathways[33][36]. Radial spokes serve as signaling transduction hubs that couple dynein activity to the central pair apparatus, enabling coordinated regulation of axonemal beat frequency and waveform characteristics[7].\n\nIn the context of astrocyte biology and astrocytoma, ciliary dyneins and radial spoke proteins play complex roles. Primary cilia in radial glia progenitors orient toward specific poles during mitosis, and this ciliary polarity becomes asymmetrically distributed during asymmetric cell division[33]. The presence or absence of cilia on daughter cells, coupled with differential centrosome inheritance, represents a fundamental mechanism for specifying progenitor versus neuronal fates[33]. In normal RGPs, primary cilia dynamics regulate Sonic hedgehog signaling and other developmental pathways that influence the balance between self-renewal and differentiation[22][33][36]. Loss or dysfunction of ciliary axonemal proteins would therefore impair this developmental plasticity, potentially forcing RGPs toward particular cell fate outcomes while simultaneously disrupting normal ciliary-dependent signaling.\n\nFor astrocytoma specifically, dysregulation of primary ciliary function could alter developmental signal reception, impair normal checkpoint mechanisms, and affect the balance between proliferation and differentiation that becomes deranged during transformation. The DNAH, DNAI, and radial spoke genes collectively encode most of the core structural machinery required for axonemal function, and their coordinated expression is essential for ciliogenesis and ciliary maintenance[1][3][4][7][10][26]. Mutations or downregulation of multiple genes in this subcategory would lead to primary ciliary dysfunction, a phenotype termed \"primary ciliary dyskinesia\" when affecting motile cilia, though altered expression in astrocytoma contexts would likely reflect dysregulation rather than complete loss-of-function.\n\n---\n\n## Centrosomal Architecture and Centriole Biogenesis: Centrosome Organization Program\n\nA second major gene program governing centrosomal organization and centriole biogenesis includes CCDC30, CCDC40, CCDC146, CCDC170, CEP83, PCM1, CFAP206, CFAP221, and related factors[10][21][33]. The centrosome serves as the primary microtubule organizing center (MTOC) and consists of a pair of centrioles embedded within pericentriolar material (PCM). This program encompasses genes required for centriole duplication, PCM assembly, and the subcellular localization of centrosomal proteins. PCM1 (pericentriolar material 1) recently emerged as a critical regulator of centrosome asymmetry during asymmetric cell division of radial glia progenitors[33].\n\nPCM1 localizes asymmetrically to the mother centrosome and facilitates the assembly of Par-3-containing complexes on polarized endosomes, thereby coupling centrosome asymmetry to polarized trafficking during RGP division[33]. The mother centrosome (older centriole) differs from the daughter centrosome in protein composition, organizing capacity, and ciliogenic potential[33]. During asymmetric division of RGPs, differential centrosome inheritance—whereby the mother centrosome preferentially goes to the progenitor daughter cell and the daughter centrosome to the neuronal daughter cell—represents one mechanism for cell fate specification[33].\n\nLoss of pcm1 in zebrafish RGPs disrupts endosome dynamics and increases neuronal differentiation at the expense of progenitor self-renewal[33]. This represents a critical functional link: genes governing centrosome asymmetry directly regulate whether RGPs self-renew or differentiate. In astrocytoma contexts, dysregulation of this program could promote either uncontrolled proliferation (through enhanced self-renewal at the expense of differentiation) or aberrant differentiation (through failure to maintain progenitor identity). The CCDC and CEP gene families also coordinate with centrosomal proteins to establish the proper microtubule nucleation capacity and PCM density required for normal cell cycle progression[10][33].\n\n---\n\n## Microtubule-Associated Proteins and Cytoskeletal Dynamics: Tubulin and Microtubule Organization Program\n\nMultiple genes within the cohort encode microtubule-binding proteins, tubulin modifying enzymes, and proteins that regulate microtubule dynamics, including TUBA1A (alpha-tubulin), TEKT1 (tektin, an axonemal protein), TTLL9 (tubulin tyrosine ligase-like 9, which catalyzes polyglutamylation of tubulin), TTC26, TTC29, TTC23L, TTC34, PACRG (parkin co-regulated protein), and others[33][36]. Tubulins are the fundamental structural units of microtubules, and post-translational modifications such as polyglutamylation and tyrosination regulate microtubule stability, motor protein binding, and cellular functions including cell migration, polarity, and spindle formation[36].\n\nIn radial glia progenitors and astrocytes, microtubule dynamics regulate both the establishment of cell polarity (critical for asymmetric division) and the guidance of cellular processes[22][33]. The microtubule cytoskeleton serves as a track for intracellular transport, positioning of organelles, and structural support for cellular projections. During asymmetric division of RGPs, the microtubule array becomes asymmetrically organized, with microtubules more abundant around the mother centrosome[33]. Proteins that modify tubulin or regulate microtubule stability therefore directly influence whether an RGP divides symmetrically (both daughters progenitors) or asymmetrically (one progenitor, one differentiating daughter).\n\nThe relevance to astrocytoma is substantial: astrocytomas are characterized by aberrant proliferation and disrupted differentiation, both processes that depend critically on proper microtubule organization and dynamics. Dysregulation of tubulin modification enzymes or microtubule-associated proteins could impair normal checkpoint control, enhance aberrant migration, or disrupt the developmental asymmetry that normally constrains progenitor proliferation.\n\n---\n\n## Endosomal Trafficking and Polarized Transport: Endosomal Trafficking Program\n\nA specialized program governing endosomal trafficking and polarized transport includes RAB-family GTPases (RAB5B, RAB11A referenced in source 33), PAR3 (PARD3B is included in the cohort), dynein-related proteins (DYNLRB2, referenced as part of dynein light chain complexes), and associated factors[21][33]. This program is particularly relevant to the asymmetric division program in RGPs, as it governs the preferential inheritance of specific endosomal compartments to one daughter cell during asymmetric division[33].\n\nPCM1 physically associates with Par-3 and Rab-family proteins on specialized endosomes termed \"Dld endosomes\" (directionally localized endosomes)[33]. These endosomes accumulate in the central zone of RGPs during mitosis and carry polarizing factors that influence daughter cell fate[33]. The transition from Rab5b-positive (early endosomal) to Rab11a-positive (recycling endosomal) compartments represents a key regulatory step that facilitates asymmetric endosome distribution[33]. Loss of this sorting function would disrupt the molecular asymmetries that normally distinguish progenitor from differentiating daughter cells.\n\nIn astrocytoma contexts, dysregulation of endosomal trafficking could impair receptor recycling, alter signaling intensity and duration (particularly for trophic factors like BDNF and TRK receptor signaling discussed below), and disrupt the polarization mechanisms that normally control differentiation programs[29].\n\n---\n\n## Transcriptional Networks Controlling Glial Fate and Neurogenesis: Transcription Factor Program\n\nA critical program comprises transcription factors that govern the balance between neurogenic and gliogenic fate decisions, including SOX5, SOX family factors, and transcriptional regulators that influence proneural versus pro-gliogenic pathways[17][19][22]. SOX5 is a member of the SOXD subfamily of transcription factors that regulates chromatin accessibility during developmental transitions[17][19][22].\n\nRecent research demonstrates that SOX5 represents a convergence point for multiple developmental pathways[19][22]. In radial glia progenitors, SOX5 expression is modulated by phosphorylation state and post-translational modifications[17]. A particular variant, Ascl1 SA6 (a phosphorylation-resistant form of ASCL1), preferentially drives GABAergic neuronal differentiation from astrocytes[17]. However, when modified to include microRNA-binding sites (Ascl1 SA6-124T), this transcription factor shows reduced neurogenic capacity and increased bifurcation toward oligodendrocyte and glutamatergic neuronal fates[17].\n\nThis demonstrates that the same transcription factor can be fine-tuned through multiple regulatory mechanisms to produce distinct cellular outcomes. In astrocytoma contexts, dysregulation of this program could promote aberrant gliogenic expansion (enhanced astrocyte formation with loss of differentiation capacity) or impair the developmental plasticity that normally constrains tumors within specific differentiation states.\n\nThe program also encompasses genes encoding transcription factors implicated in injury responses and glial reactivity. When astrocytes are activated in response to injury, they upregulate specific transcription factors including STAT3 and SOX9 that coordinate pro-inflammatory and barrier-forming gene expression programs[22][39]. In chronic injury or disease states (including tumor contexts), astrocytes maintain persistent activation states characterized by mixed phenotypes featuring both neuroinflammatory and neurodegenerative elements[39]. Dysregulation of the transcriptional factors controlling these states could lock astrocytes into aberrant activation states that promote tumorigenesis.\n\n---\n\n## Tyrosine Kinase Signaling and Neurotrophin Receptor Pathways: Growth Factor Signaling Program\n\nA program controlling growth factor signaling includes NTRK2 (neurotrophic receptor tyrosine kinase 2), which serves as the receptor for brain-derived neurotrophic factor (BDNF)[11][29][38]. NTRK2 also appeared as part of an oncogenic fusion protein (TRIM24::NTRK2) identified in pediatric diffuse high-grade gliomas[11][38]. When fused, NTRK2 becomes constitutively activated, driving proliferation through enhanced phosphorylation of downstream effectors including AKT (protein kinase B), ERK1/2, and STAT3[2][11][38][44].\n\nBDNF-NTRK2 signaling normally regulates neuronal survival, growth, and synaptic plasticity in the nervous system[29]. Elevated BDNF in the tumor microenvironment increases peripheral innervation by signaling through TRK2 receptors, demonstrating that BDNF-NTRK2 axis actively shapes tissue architecture and cell recruitment in tumors[29]. In astrocytes specifically, NTRK2 activation through BDNF signaling can promote astrocytic differentiation and maturation, though the consequences of constitutive activation (as occurs in fusion-bearing tumors) remain less clear[29].\n\nThe program also includes AKT1, which serves as a major hub for multiple signaling pathways[2][34]. AKT phosphorylates numerous substrates controlling cell survival, proliferation, and metabolic state[2][34]. Primary cilia regulate AKT signaling through modulation of multiple upstream pathways, and disruption of ciliary function can alter AKT activity levels[2]. In the context of astrocytoma, hyperactivation of AKT1 (either through NTRK2 fusion, through mutations in phosphatase and tensin homolog (PTEN), or through amplification of the PI3K pathway) promotes uncontrolled proliferation and survival[2][34].\n\n---\n\n## Tumor Suppressor and Cell Cycle Control: TP53 and Cell Cycle Checkpoint Program\n\nThe cohort includes TP63, a p53 family member that shares structural and functional homology with TP53 itself (which is not in the list but is critical context)[12][15]. TP53 functions as a master tumor suppressor that responds to cellular stresses including DNA damage, hypoxia, and oncogenic signaling[12][15]. TP53 mutations are found in a substantial fraction of astrocytomas and other CNS malignancies[13]. The p.Arg175His (p.R175H) mutation represents a hotspot mutation in TP53 that loses normal tumor suppressor function while acquiring gain-of-function properties that promote cell migration and invasion[12].\n\nTP63 regulates epithelial cell identity and differentiation[20], and dysregulation of TP63 could alter the developmental plasticity of astrocytic progenitors. Additionally, the cohort includes genes regulating the G2/M cell cycle checkpoint, including WEE1 (G2 checkpoint kinase)[48]. WEE1 phosphorylates and inactivates cyclin-dependent kinase 1 (CDK1), thereby preventing mitotic entry and allowing time for DNA repair[48]. Dysregulation of WEE1—either through upregulation (which might delay cell cycle progression) or downregulation (which might promote premature mitotic entry with incomplete DNA replication)—fundamentally alters cell cycle fidelity[48].\n\n---\n\n## Metabolic Reprogramming and Energy Production: Glycolytic and Mitochondrial Metabolism Program\n\nMultiple genes in the cohort regulate metabolic states and energy production, including SUCLG2 (succinate-CoA ligase), which functions in both the citric acid cycle and fatty acid metabolism[44]. Recent research demonstrates that SUCLG2 plays a crucial role in regulating lactate metabolism in glioblastoma[44]. Lactate represents both a waste product of glycolysis and a critical metabolic fuel; at concentrations of 10-15 mM (which occur in tumor tissues), lactate significantly reverses cell viability loss under low-glucose conditions[44]. Knockdown of SUCLG2 in glioblastoma cells significantly reduced lactate concentrations within tumor tissue and impaired mitochondrial membrane potential, ultimately decreasing proliferation[44].\n\nThis program also encompasses genes regulating long non-coding RNAs (lncRNAs) that modulate glycolytic enzyme expression and signaling[47]. LncRNAs including those encoded by genes such as RMST (r-spondin family members and transmembrane proteins) influence metabolic adaptation by modulating glycolytic enzymes, transcription factors, and signaling pathways[47]. These features indicate lncRNAs as promising diagnostic biomarkers and therapeutic targets in cancer metabolism[47].\n\nFor astrocytomas specifically, metabolic reprogramming represents a hallmark of transformation[44]. Tumor cells preferentially adopt glycolytic metabolism even under normoxic conditions (the Warburg effect), generating substantial lactate that accumulates in the tumor microenvironment[44]. This metabolic shift supports rapid proliferation while providing selective pressure on tumor cell populations for lactate utilization and tolerance. Dysregulation of the metabolic genes in this cohort would amplify these glycolytic-to-oxidative balance shifts characteristic of astrocytoma.\n\n---\n\n## Centrosome Asymmetry and Asymmetric Cell Division: The Developmental Plasticity Program\n\nA unifying program connects multiple subcategories above: the control of centrosome asymmetry, asymmetric cell division modes, and the resulting specification of distinct daughter cell fates in radial glia progenitors. This program integrates centrosomal proteins (PCM1, CCDC proteins, CEP family members), microtubule regulators (TUBAs, TTCs, PACRG), endosomal trafficking factors (PAR3, RAB proteins, DYNLRB2), and transcriptional regulators (SOX5, transcription factors responsive to injury signals)[17][22][33].\n\nThe empirical evidence for this integrated program is compelling: PCM1 loss in zebrafish RGPs disrupts the normal distribution of endosomes between daughter cells, impairs Par-3 localization to polarized endosomes, and fundamentally alters the balance between progenitor (P/P symmetric, self-renewing divisions) and neuronal (N/N symmetric, differentiation divisions) versus asymmetric (P/N) divisions[33]. Specifically, pcm1 knockdown decreases P/P and P/N divisions from 42% and 39% (in controls) to lower percentages while increasing N/N divisions to 49% of observed divisions[33]. This demonstrates that loss of centrosome asymmetry programs drives increased differentiation at the expense of progenitor self-renewal.\n\nIn the context of astrocytoma initiation and progression, a critical question becomes: would dysregulation of this program promote or inhibit tumorigenesis? If loss of the program drives differentiation, it might initially suppress proliferation. However, if the program is dysregulated in ways that promote symmetric self-renewing divisions while simultaneously acquiring mutations that impair differentiation capacity (through TP53 loss, for instance), the result would be uncontrolled progenitor expansion—precisely the phenotype characterizing astrocytoma. Additionally, loss of the normal developmental plasticity controlled by this program would eliminate a critical constraint on cellular behavior, potentially allowing oncogenic transformations to proceed unopposed.\n\n---\n\n## Ciliary and Developmental Signaling Integration: The Developmental Sensing Program\n\nBeyond structural ciliary components, the cohort includes genes regulating ciliary signaling pathways and developmental responsiveness. Primary cilia function as sensory organelles that receive and transduce Hedgehog signaling, Wnt signaling, FGF signaling, and other developmental pathways[22][33][36][49]. The presence or activity state of primary cilia fundamentally determines whether astrocytes and RGPs respond to developmental signals or remain refractory[22][33][36].\n\nThis has direct relevance to astrocytoma: during normal development, astrocytes differentiate from RGPs in response to specific developmental cues, and this differentiation process fundamentally limits proliferation capacity[33][39]. Astrocytes represent the terminal differentiated state, though they retain some plasticity and can be reprogrammed back toward more progenitor-like states under specific experimental conditions[17][39]. In astrocytoma, loss of developmental sensing—whether through ciliary dysfunction, defects in signaling transduction, or loss of transcriptional responsiveness to developmental signals—would impair the normal constraints on RGP proliferation that normally drive differentiation.\n\nThe program integrates ciliary structural genes (dynein arms, radial spokes) with transcriptional factors and signaling effectors that mediate developmental responses. For instance, RGPs that lack functional primary cilia show impaired Sonic hedgehog signaling and altered specification toward particular neuron subtypes[33]. If RGPs lose ciliary function before acquiring oncogenic mutations that drive proliferation (such as TP53 loss), the resulting cells would be proliferation-prone, resistant to differentiation signals, and susceptible to further transformation.\n\n---\n\n## Long Non-Coding RNAs and Regulatory Networks: Post-Transcriptional Control Program\n\nThe gene list includes multiple long non-coding RNAs (LINC genes, including LINC00271, LINC00609, LINC00880, LINC00894, LINC01088, LINC01091, LINC01094, LINC01602, LINC02018, LINC02055) and lncRNA-associated genes. These genes regulate gene expression post-transcriptionally through multiple mechanisms including modulation of microRNA (miRNA) activity, chromatin accessibility, and signaling pathway engagement[47][48].\n\nRecent studies demonstrate that lncRNAs play critical roles in cancer metabolism, particularly in regulating glycolytic reprogramming[47]. VIM-AS1 (vimentin antisense RNA 1) represents an exemplary lncRNA whose knockdown inhibits glioma cell proliferation and migration while increasing cell apoptosis through modulation of WEE1 (the G2 checkpoint kinase)[48]. This demonstrates that dysregulation of specific lncRNAs contributes to malignant glioma phenotypes.\n\nIn astrocytomas specifically, dysregulation of the lncRNA program could simultaneously enhance metabolic reprogramming, suppress differentiation programs, and impair checkpoint control—a combination of alterations that powerfully promotes malignant progression. The lncRNAs in this cohort likely act in concert with microRNAs and transcription factors to create integrated regulatory networks that determine astrocytic cell fate and proliferation.\n\n---\n\n## Cell Adhesion, Extracellular Matrix Interactions, and Cellular Context Program\n\nA final program encompasses genes regulating cell adhesion, extracellular matrix (ECM) interactions, and the cellular microenvironment, including PLEKHA5, PLEKHA7, PTPRQ (protein tyrosine phosphatase receptor Q), and others[24][40][42]. The extracellular matrix surrounding astrocytes and gliomas contains hundreds of ECM components whose expression is dysregulated in glioblastoma compared to normal brain[42].\n\nSpatial transcriptomic studies reveal that at least four different glioblastoma cell populations express unique ECM signatures with spatial enrichment in distinct intratumor regions[42]. Vascular endothelial cells and microglia/macrophages display largely non-overlapping ECM expression patterns[42]. This spatial heterogeneity in ECM composition creates distinct microenvironmental niches that support different tumor cell states and functions. Dysregulation of genes controlling ECM interactions would alter how astrocytic tumor cells respond to their microenvironment, potentially promoting invasion, angiogenesis, and immune suppression[24][40][42].\n\nAdditionally, pericytes that line blood vessels orchestrate tumor-restraining microenvironments; their depletion through genetic engineering results in accelerated tumor progression and shortened survival[40]. Pericytes express paracrine factors that suppress immune cell polarization toward suppressive (M2-like) phenotypes and maintain blood-brain barrier integrity[40]. Loss of pericyte-astrocyte interactions could unleash immune suppressive programs while simultaneously compromising BBB function, both features characteristic of advanced astrocytomas.\n\n---\n\n## Astrocyte Activation and Neuroinflammatory Responses: Reactive Astrocyte Program\n\nRecent research characterizing astrocyte transcriptomics following traumatic brain injury reveals that astrocyte activation states evolve dynamically over time, with distinct transcriptional signatures associated with acute pro-inflammatory, subacute transitional, and chronic neurodegenerative phases[39]. Acute astrocyte activation features upregulation of pro-inflammatory cytokines (TNF, IL-1β, IL-17rc), chemokines (CCL2, CXCL10), and immediate early genes (Junb, Egr1)[39].\n\nIn the subacute phase, astrocyte transcriptomes shift away from acute inflammation and toward signatures associated with early neurodegenerative processes, including upregulation of synapse pruning mediators (Sparc, Mertk, C1q components)[39]. The chronic phase reveals sustained upregulation of genes involved in mitochondrial and neuronal apoptotic pathways, suggesting ongoing cellular stress[39]. Importantly, chronic-phase astrocytes show increased expression of Ndrg1 (highly expressed in brain tumors including astrocytoma) and reduced expression of Rbpj (which when deleted promotes neurogenesis)[39].\n\nIn the context of astrocytoma, these activation signatures become relevant because tumor-associated astrocytes likely adopt mixed phenotypes reflecting both reactivity elements and tumor-promoting features. Dysregulation of genes controlling the transition between different astrocytic activation states could lock tumor-associated astrocytes in particular phenotypic states—either pro-inflammatory states that support immune infiltration or neurodegenerative states that impair normal homeostatic functions. The genes in the provided cohort likely participate in specifying and maintaining distinct astrocytic states through their effects on transcription factor activity, metabolic state, and signaling responsiveness.\n\n---\n\n## Genomic and Transcriptomic Evidence for Multi-Gene Program Dysregulation in Astrocytoma\n\nRecent comprehensive characterization studies of pediatric high-grade gliomas identify the molecular heterogeneity characteristic of these tumors[11][38]. RNA-sequencing reveals that tumors display evolving mutational landscapes over time, acquiring additional pathogenic variants and altering their dependencies on particular oncogenic drivers[11][38]. For instance, a TRIM24::NTRK2 fusion initially drives proliferation through MAPK and PI3K pathway activation, with NTRK2 phosphorylation levels showing 6-fold increases over wild-type levels[11][38].\n\nHowever, over time, tumors become less reliant on the TRIM24::NTRK2 driver and activate alternative oncogenic pathways including FGFR1-3, FLT1, KIT, and MET expression[11][38]. This demonstrates that gliomas possess substantial plasticity in the oncogenic drivers they employ, likely reflecting the heterogeneous microenvironmental pressures and selective advantages within different tumor regions[11][38]. Pathway analysis reveals that tumors upregulate heterotrimeric G-protein signaling, T-cell activation pathways, B-cell activation pathways, and MAPK signaling over time[11][38].\n\nThis plasticity in molecular drivers and transcriptional states likely depends critically on the developmental programs encoded by genes like those in the provided cohort. If astrocytic tumors retain functional developmental plasticity programs (including the centrosome asymmetry, ciliary signaling, and transcriptional regulatory networks described above), they could readily adapt to changing microenvironmental pressures. Conversely, if these programs become dysregulated or lost, tumor cells might become trapped in particular differentiation or proliferation states, potentially creating vulnerabilities amenable to therapeutic targeting.\n\n---\n\n## Integrated Gene Program Summary: Functional Clusters and Predicted Impacts\n\nThe analysis identifies approximately twelve major gene programs within the provided cohort, each operating across multiple scales of organization from molecular signaling to cellular division modes to tissue-level microenvironment interactions. The programs are not independent but rather form an integrated network such that dysregulation of any single program affects the others. For instance, loss of ciliary function (through dynein or radial spoke gene dysregulation) impairs developmental sensing pathways that normally respond to signals received by the cilium, thereby disrupting the transcriptional responses that drive differentiation and constrain proliferation.\n\nCollectively, dysregulation of multiple genes from these programs would fundamentally alter astrocyte and astrocyte progenitor biology in ways directly relevant to astrocytoma initiation and progression. The predicted cellular impacts include enhanced proliferation (through TP53/TP63 dysregulation and loss of differentiation signals), impaired developmental plasticity (through ciliary dysfunction and transcriptional network disruption), altered metabolic state (through SUCLG2 and lncRNA dysregulation), and enhanced responsiveness to microenvironmental signals including cytokines and growth factors (through signaling pathway reactivation).\n\n---\n\n## Conclusion: Gene Programs as Integrated Systems Controlling Astrocytic Fate and Tumorigenesis\n\nThe provided gene list encompasses multiple interconnected programs that collectively govern the development, differentiation, and proliferation of astrocytes and their precursors. Rather than representing a collection of independently dysregulated genes, the cohort likely functions as an integrated system wherein multiple gene dysregulations cooperatively drive astrocytoma formation and progression.\n\nThe programs operate across hierarchical levels: from primary ciliary structure and motility (DNAH, DNAI genes) through centrosomal organization and asymmetric cell division (PCM1, CCDC genes) to transcriptional networks controlling cell fate decisions (SOX5, transcription factor programs) to metabolic reprogramming and signaling pathway activation (SUCLG2, lncRNAs, NTRK2). Dysregulation at any level propagates effects through the integrated system, ultimately resulting in the transformed phenotype characteristic of astrocytoma.\n\nRecent advances in astrocytoma genomics and transcriptomics reveal that these tumors display remarkable molecular heterogeneity and plasticity, likely reflecting the retained developmental plasticity of their cell-of-origin (radial glia progenitors or early differentiating astrocytes). The gene programs identified in this analysis likely underlie this plasticity. Understanding how dysregulation of these programs contributes to transformation offers opportunities for identifying novel therapeutic targets and patient stratification strategies based on the specific gene program alterations present in individual tumors.\n\nThe following JSON structure encodes these findings in structured format, prioritizing programs with multiple supporting genes and strong literature evidence while noting genes from the input list that directly participate in each program.\n\n---\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"context\": {\n    \"cell_type\": \"Astrocytes and radial glia progenitors\",\n    \"disease\": \"Astrocytoma\",\n    \"tissue\": \"Brain (central nervous system)\"\n  },\n  \"input_genes\": [\n    \"DNAH11\", \"EFHC2\", \"SERPINI2\", \"CFAP52\", \"DRC1\", \"ERICH3\", \"C8ORF34\", \"C4ORF47\", \"SLC47A2\", \"CFAP54\", \"SLC9C2\", \"DNAAF1\", \"NAA11\", \"CFAP57\", \"SPAG1\", \"SPAG17\", \"SPATA17\", \"MOK\", \"ARMC2\", \"CFAP61\", \"FANK1\", \"CASC1\", \"NEK11\", \"CFAP46\", \"EFCAB6\", \"DRC7\", \"CFAP221\", \"CFAP206\", \"CFAP100\", \"DTHD1\", \"NPHP1\", \"RGS22\", \"RMST\", \"CFAP47\", \"DYNLRB2\", \"NEK5\", \"ROPN1L\", \"EFCAB12\", \"CCDC40\", \"CCDC30\", \"RPGR\", \"EFCAB2\", \"CCDC170\", \"CCDC146\", \"CFAP69\", \"ANKRD45\", \"ANKFN1\", \"VWA3B\", \"TTC34\", \"TTLL9\", \"AC099788.1\", \"DNAI1\", \"IQUB\", \"DNAH9\", \"DNAH7\", \"DNAH6\", \"VWA3A\", \"WDR49\", \"FHAD1\", \"WDR63\", \"DNAH5\", \"WDR78\", \"LINC01088\", \"AC013470.2\", \"ZBBX\", \"DNAH12\", \"LINC00880\", \"DCDC1\", \"AC104078.2\", \"AC105052.5\", \"TTC29\", \"PLTP\", \"CFAP70\", \"MAP3K19\", \"FRMPD2\", \"CFAP73\", \"MAATS1\", \"TCTEX1D1\", \"TEKT1\", \"ODF3B\", \"TMEM232\", \"LRRC9\", \"LRRC6\", \"PTPRQ\", \"AK1\", \"PACRG\", \"AGBL4\", \"PPP1R42\", \"LRGUK\", \"CFAP43\", \"NTRK2\", \"PARD3B\", \"AC004949.1\", \"NOL4\", \"NEK10\", \"LINC00609\", \"LINC00894\", \"LINC01091\", \"LINC01094\", \"LINC01602\", \"LINC02018\", \"LINC02055\", \"LMNTD1\", \"LRAT\", \"LRIG3\", \"LRP1B\", \"LRRC23\", \"LRRIQ1\", \"MAOB\", \"MIR99AHG\", \"MLIP\", \"MLIP-AS1\", \"MYCBPAP\", \"MYLK3\", \"NEBL\", \"NEGR1\", \"NCKAP5\", \"RFTN2\", \"PARP15\", \"TPPP3\", \"SPATA6L\", \"SPEF2\", \"SRPX2\", \"STK33\", \"SULT1C4\", \"SYNE1\", \"SYNM\", \"SYTL4\", \"TCP11L2\", \"TMEM163\", \"TMEM67\", \"TOGARAM2\", \"TP63\", \"TRDN\", \"PAWR\", \"TSGA10\", \"TTC23L\", \"TTC26\", \"TUBA1A\", \"TWSG1\", \"ULK4\", \"USP2-AS1\", \"USP43\", \"WDR66\", \"WLS\", \"ZFP36L1\", \"ZFPM2\", \"ZMYND10\", \"SPATA18\", \"SPA17\", \"SOX5\", \"SORBS2\", \"PDZRN4\", \"PIK3C2G\", \"PLCH1\", \"PLCZ1\", \"PLEKHA5\", \"PLEKHA7\", \"PPIL6\", \"PTCHD1-AS\", \"RALGPS2\", \"RASSF4\", \"RERGL\", \"LIMCH1\", \"RFX2\", \"RFX4\", \"RNF165\", \"RNF19A\", \"ROBO2\", \"RORB\", \"RPS6KA5\", \"RTN1\", \"SCIN\", \"SDK1\", \"SGSM1\", \"SLC14A1\", \"SLC35F4\", \"SLC7A11\", \"SLCO1A2\", \"LINC00271\", \"FIGN\", \"LHFPL6\", \"CD36\", \"AL357093.2\", \"AL390957.1\", \"AL513166.1\", \"ANGPT1\", \"ANKDD1B\", \"ANTXR1\", \"ANXA1\", \"AR\", \"ARMC3\", \"ARMC4\", \"B3GLCT\", \"BBOX1\", \"BCL2\", \"BMPR1B\", \"BRINP3\", \"C1ORF198\", \"C1ORF87\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Primary Ciliary Axonemal Dyneins and Motor Apparatus\",\n      \"description\": \"Genes encoding outer dynein arm (ODA), inner dynein arm (IDA), and dynein regulatory complex components that comprise the motor machinery of axonemal microtubules in primary cilia. These proteins convert ATP hydrolysis into mechanical force driving ciliary beating and motility. Dysregulation impairs ciliary-dependent mechanosensing and developmental signaling, disrupting normal developmental constraints on astrocyte proliferation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"ATP hydrolysis-coupled ciliary motility\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"GJA1 (connexin) is a component of gap junctions relevant to intercellular communication altered in glioma\"\n            },\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"BDNF is involved in neural development and survival, with polymorphisms associated with cancer-related pathology\"\n            },\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"KIF11 localizes to basal bodies of primary cilia and reduction alters cilia dynamics\"\n            }\n          ],\n          \"genes\": [\n            \"DNAH5\",\n            \"DNAH6\",\n            \"DNAH7\",\n            \"DNAH9\",\n            \"DNAH11\",\n            \"DNAH12\",\n            \"DNAI1\",\n            \"DNAAF1\",\n            \"ROPN1L\",\n            \"DRC1\",\n            \"DRC7\"\n          ]\n        },\n        {\n          \"name\": \"Radial spoke and central pair signaling transduction\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"CEP290 mutations impair protein interaction and localize to centrosomes, compromising cilia formation relevant to developmental timing\"\n            }\n          ],\n          \"genes\": [\n            \"ROPN1L\",\n            \"DRC1\",\n            \"DRC7\",\n            \"CFAP46\",\n            \"CFAP47\",\n            \"CFAP52\",\n            \"CFAP54\",\n            \"CFAP57\",\n            \"CFAP61\",\n            \"CFAP69\",\n            \"CFAP70\",\n            \"CFAP73\",\n            \"CFAP100\",\n            \"CFAP206\",\n            \"CFAP221\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Axonemal nine-plus-two microtubule apparatus\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"KIF11 localization to primary cilia basal bodies indicates critical role in ciliogenesis\"\n            }\n          ],\n          \"genes\": [\n            \"DNAH5\",\n            \"DNAH6\",\n            \"DNAH7\",\n            \"DNAH9\",\n            \"DNAH11\",\n            \"DNAH12\",\n            \"TEKT1\",\n            \"CCDC30\",\n            \"CCDC40\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Impaired primary cilium-dependent developmental signal reception (Hedgehog, Wnt, FGF pathways)\",\n        \"Disrupted mechanotransduction through ciliary bending\",\n        \"Altered astrocyte developmental plasticity and progenitor maintenance\",\n        \"Enhanced susceptibility to uncontrolled proliferation through loss of differentiation signals\",\n        \"Dysregulated ciliary polarity during asymmetric cell division\"\n      ],\n      \"evidence_summary\": \"The cohort contains at least 15 genes encoding outer dynein arms (DNAH family), inner dynein arm components (DNAI, DNAAF), and radial spoke proteins (DRC, ROPN1L). These proteins form the core structural and regulatory machinery enabling ciliary motility. In radial glia progenitors and astrocytes, primary cilia mediate developmental signal reception and mechanosensingvia Sonic hedgehog, Wnt, and other pathways. Loss or dysregulation of dynein function would impair these ciliary-dependent signaling pathways, disrupting normal developmental constraints that maintain RGP multipotency while limiting proliferation. Recent evidence demonstrates that ciliary dysfunction alters developmental fate specification in RGPs, with downstream consequences for neurogenesis and gliogenesis balance.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"GJA1 and gap junction proteins implicated in cell-cell communication altered in glial tumors\"\n        },\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"BDNF role in neural development with implications for tumor biology\"\n        },\n        {\n          \"source_id\": \"7\",\n          \"notes\": \"KIF11 localizes to primary cilia basal bodies\"\n        },\n        {\n          \"source_id\": \"10\",\n          \"notes\": \"CEP290 interactions with NPHP5 relevant to cilia formation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"DNAH5\",\n        \"DNAH6\",\n        \"DNAH7\",\n        \"DNAH9\",\n        \"DNAH11\",\n        \"DNAH12\",\n        \"DNAI1\",\n        \"DNAAF1\",\n        \"ROPN1L\",\n        \"DRC1\",\n        \"DRC7\",\n        \"CFAP46\",\n        \"CFAP47\",\n        \"CFAP52\",\n        \"CFAP54\",\n        \"CFAP57\",\n        \"CFAP61\",\n        \"CFAP69\",\n        \"CFAP70\",\n        \"CFAP73\",\n        \"CFAP100\",\n        \"CFAP206\",\n        \"CFAP221\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CCDC39\",\n          \"CCDC103\",\n          \"LRRC6\",\n          \"SPAG1\",\n          \"HYDIN\",\n          \"CCDC114\",\n          \"DYX1C1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"10\",\n            \"notes\": \"Multiple CCDC and other axonemal proteins required for cilia assembly\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Centrosome Asymmetry and Asymmetric Cell Division Control\",\n      \"description\": \"A program governing centrosome organization, pericentriolar material assembly, and asymmetric inheritance of centrosomes during cell division. Includes PCM1, CCDC proteins, CEP83, and associated factors. During asymmetric division of radial glia progenitors, this program determines whether daughter cells inherit mother or daughter centrosomes, thereby directing progenitor versus neuronal fate specification. In astrocytoma, dysregulation would disrupt developmental plasticity and potentially promote symmetric self-renewing divisions.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Pericentriolar material assembly and centrosome organization\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"PCM1 coordinates centrosome asymmetry with polarized endosome trafficking in radial glia progenitors; loss of pcm1 disrupts endosome dynamics\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC30\",\n            \"CCDC40\",\n            \"CCDC146\",\n            \"CCDC170\"\n          ]\n        },\n        {\n          \"name\": \"Asymmetric centrosome inheritance and segregation\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"Mother centrosome preferentially localizes PCM1 and associates with Cep83 during mitosis; differential inheritance specifies progenitor versus differentiated fates\"\n            }\n          ],\n          \"genes\": [\n            \"PARD3B\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Pericentriolar material (PCM) complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"PCM1 exists in cloud-like patterns around centrosomes with asymmetric distribution along cell division axis\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC30\",\n            \"CCDC40\",\n            \"CCDC146\",\n            \"CCDC170\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Disrupted specification of progenitor versus differentiating daughter cells during RGP division\",\n        \"Increased symmetric self-renewing divisions at expense of asymmetric divisions producing differentiating progeny\",\n        \"Loss of developmental plasticity control mechanisms\",\n        \"Enhanced proliferation potential through maintenance of progenitor identity in daughter cells\",\n        \"Altered coupling between centrosome inheritance and polarized endosome trafficking\"\n      ],\n      \"evidence_summary\": \"Recent work identifies PCM1 as a critical regulator of centrosome asymmetry in radial glia progenitors. PCM1 localizes asymmetrically to the mother (posterior) centrosome and facilitates Par-3 assembly on polarized endosomes. Loss of pcm1 increases neuronal (N/N) divisions from 19% to 49% while decreasing progenitor-producing divisions (P/P from 42% to lower levels). This demonstrates that centrosome asymmetry programs directly specify RGP division modes. The program includes multiple CCDC genes (CCDC30, CCDC40, CCDC146, CCDC170) required for PCM assembly, and PARD3B which forms part of the polarization complex. In astrocytoma contexts, dysregulation of this program could promote enhanced self-renewal while disrupting normal differentiation constraints.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"33\",\n          \"notes\": \"PCM1 coordinates centrosome asymmetry with polarized endosome trafficking; loss alters progenitor division modes\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CCDC30\",\n        \"CCDC40\",\n        \"CCDC146\",\n        \"CCDC170\",\n        \"PARD3B\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CEP83\",\n          \"CEP76\",\n          \"CEP350\",\n          \"γ-tubulin\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"33\",\n            \"notes\": \"PCM1 associates with Cep83 on mother centrosome; other CEPs required for PCM function\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Microtubule Organization and Post-Translational Tubulin Modification\",\n      \"description\": \"Genes encoding tubulins, tubulin-modifying enzymes (particularly polyglutamylases), and microtubule-associated proteins that regulate microtubule stability, organization, and dynamics. TTLL9 catalyzes polyglutamylation of tubulin, a modification regulating microtubule-motor protein interactions. In RGPs, asymmetric microtubule organization contributes to cell polarity and division mode determination. Dysregulation alters both developmental plasticity and cell cycle checkpoint control.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Tubulin polyglutamylation and post-translational modification\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"DNA replication fork speed acts as pacer in cortical development, connecting cell cycle dynamics to developmental timing\"\n            }\n          ],\n          \"genes\": [\n            \"TTLL9\",\n            \"PACRG\"\n          ]\n        },\n        {\n          \"name\": \"Microtubule nucleation and organization from centrosomes\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"Microtubules more abundant around posterior (mother) centrosome during RGP mitosis\"\n            }\n          ],\n          \"genes\": [\n            \"TUBA1A\",\n            \"TTC26\",\n            \"TTC29\",\n            \"TTC23L\",\n            \"TTC34\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Microtubule lattice and associated protein complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"Microtubule organization essential for polarized radial glial scaffold formation\"\n            }\n          ],\n          \"genes\": [\n            \"TUBA1A\",\n            \"TEKT1\",\n            \"TTLL9\",\n            \"PACRG\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Altered microtubule stability and dynamics affecting spindle formation and cytokinesis\",\n        \"Disrupted cell polarity establishment and maintenance\",\n        \"Impaired asymmetric distribution of developmental determinants during mitosis\",\n        \"Dysregulated intracellular transport of signaling complexes and organelles\",\n        \"Enhanced cell cycle dysregulation through altered checkpoint control\"\n      ],\n      \"evidence_summary\": \"The cohort includes TUBA1A (alpha-tubulin, the fundamental structural unit of microtubules), TTLL9 (tubulin tyrosine ligase-like 9, catalyzing polyglutamylation), PACRG (parkin co-regulated gene product, a microtubule-associated protein), and multiple TTC genes (tetratricopeptide repeat-containing proteins) that regulate microtubule function. Polyglutamylation of tubulin regulates the binding of motor proteins and other microtubule-associated factors, thereby controlling intracellular transport and organelle positioning. During RGP asymmetric division, microtubules become asymmetrically organized around the mother centrosome, contributing to cell polarity and fate specification. Dysregulation of tubulin modification enzymes or microtubule-associated proteins would impair these developmental processes while potentially disrupting cell cycle checkpoint control.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"33\",\n          \"notes\": \"Microtubule organization asymmetry during RGP division\"\n        },\n        {\n          \"source_id\": \"36\",\n          \"notes\": \"Microtubule dynamics essential for cortical development timing\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"TUBA1A\",\n        \"TTLL9\",\n        \"PACRG\",\n        \"TTC26\",\n        \"TTC29\",\n        \"TTC23L\",\n        \"TTC34\",\n        \"TEKT1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"TUBB2A\",\n          \"TUBB2B\",\n          \"TUBB3\",\n          \"MAP2\",\n          \"MAP1B\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"36\",\n            \"notes\": \"Multiple tubulin and MAP proteins required for normal microtubule function\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Endosomal Trafficking and Polarized Transport\",\n      \"description\": \"Genes governing endosomal compartmentalization, trafficking between endosomal compartments, and asymmetric inheritance of endosomes during cell division. Includes PARD3B, DYNLRB2, and factors facilitating RAB5b-to-RAB11a transitions on specialized endosomes. This program couples centrosome asymmetry to polarized distribution of signaling complexes and developmental determinants, thereby directing cell fate specification in RGPs.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Early-to-recycling endosome maturation and transition\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"PCM1 facilitates transition from Rab5b to Rab11a on recycling endosomes; loss impairs this transition\"\n            }\n          ],\n          \"genes\": [\n            \"PARD3B\",\n            \"DYNLRB2\"\n          ]\n        },\n        {\n          \"name\": \"Asymmetric endosome inheritance and polarized distribution\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"Directionally localized (Dld) endosomes accumulated in central zone during RGP anaphase; differential inheritance to daughter cells\"\n            }\n          ],\n          \"genes\": [\n            \"PARD3B\",\n            \"DYNLRB2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Early endosomal compartment (Rab5b-positive)\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"Rab5b compartments in surrounding cytoplasm; transition to Rab11a in central zone\"\n            }\n          ],\n          \"genes\": [\n            \"PARD3B\",\n            \"DYNLRB2\"\n          ]\n        },\n        {\n          \"name\": \"Recycling endosomal compartment (Rab11a-positive)\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"Par-3 and PCM1 co-localize with Rab11a in central zone of dividing RGPs\"\n            }\n          ],\n          \"genes\": [\n            \"PARD3B\",\n            \"DYNLRB2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Disrupted asymmetric distribution of signaling receptors and developmental determinants\",\n        \"Impaired ability to maintain distinct signaling states in progenitor versus differentiating daughter cells\",\n        \"Loss of developmental plasticity through disrupted coupling of endosomal trafficking to fate specification\",\n        \"Altered growth factor receptor signaling intensity through dysregulated receptor recycling\",\n        \"Enhanced proliferation through loss of endosomal trafficking-mediated differentiation signals\"\n      ],\n      \"evidence_summary\": \"PCM1 physically associates with Par-3 and Rab-family proteins on specialized directionally-localized (Dld) endosomes during RGP mitosis. These endosomes accumulate in the central zone and carry polarizing factors influencing daughter cell fate. The transition from Rab5b-positive (early endosomal) to Rab11a-positive (recycling endosomal) compartments facilitates asymmetric endosome distribution. PARD3B (Par-3 paralog) and DYNLRB2 (dynein light chain) participate in Par complex assembly and dynein-dependent endosomal transport. Loss of proper endosomal sorting would disrupt the molecular asymmetries distinguishing progenitor from differentiating daughter cells, thereby impairing normal developmental constraints.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"33\",\n          \"notes\": \"PCM1 interacts with Par-3, Dlic1, Rab11a, Rab5b on endosomes; physical coupling of centrosome asymmetry to endosomal trafficking\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PARD3B\",\n        \"DYNLRB2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"RAB5B\",\n          \"RAB11A\",\n          \"DLIC1\",\n          \"PAR3\",\n          \"PAR6\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"33\",\n            \"notes\": \"RAB GTPases and PAR complex components required for polarized endosomal trafficking\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Transcriptional Control of Glial Differentiation and Neurogenic Fate\",\n      \"description\": \"Genes encoding transcription factors and chromatin regulators that control the balance between proneural (neurogenic) and pro-gliogenic (glial-promoting) gene expression programs. SOX5 represents a key member specifying glial fates. Dysregulation of this program shifts the balance toward either uncontrolled gliogenic expansion (promoting astrocytoma) or inappropriate neurogenic differentiation. The program responds to developmental signals received through primary cilia and other developmental pathways.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Proneural-to-gliogenic transcriptional switching\",\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"Ascl1 SA6 (phosphorylation-resistant form) drives GABAergic neuronal differentiation from astrocytes; inclusion of microRNA binding sites redirects toward oligodendrocyte fates\"\n            },\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"SOX5 may suppress oncogenic PDGFB signaling during glioma development by regulating p27(Kip1)\"\n            }\n          ],\n          \"genes\": [\n            \"SOX5\"\n          ]\n        },\n        {\n          \"name\": \"Glial cell identity maintenance and astrocytic differentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"SOX9 regulates astrocyte reactivity and identity; peak-to-gene analysis shows reactive astrocyte genes associated with differentially accessible enhancers\"\n            }\n          ],\n          \"genes\": [\n            \"SOX5\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Chromatin-accessible enhancer regions controlling glial differentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"Glial cell-specific enhancer regions enriched in binding motifs for SOX9, NFI, RFX transcription factors\"\n            }\n          ],\n          \"genes\": [\n            \"SOX5\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated balance between neurogenic and gliogenic fate specification in RGPs\",\n        \"Enhanced astrocytic self-renewal at expense of neuronal differentiation\",\n        \"Loss of developmental constraints normally limiting RGP proliferation\",\n        \"Impaired ability to respond to developmental signals specifying differentiation\",\n        \"Potential acquisition of aberrant glial identity featuring both progenitor and mature astrocyte characteristics\"\n      ],\n      \"evidence_summary\": \"SOX5 (SRY-box transcription factor 5) represents a key regulator of glial fate specification that suppresses oncogenic signaling during glioma development. SOX5 may suppress PDGFB signaling effects during glioma development by regulating p27(Kip1) expression, implying a tumor-suppressive function. Recent research reveals that proneural bHLH transcription factors like ASCL1, when modified to include microRNA-binding sites, shift lineage outcomes from neurogenic toward oligodendrocyte and glutamatergic neuronal fates. This demonstrates that transcriptional fate regulators represent convergence points for multiple post-transcriptional regulatory mechanisms. In astrocytoma, dysregulation of SOX5 and related transcription factors would impair normal glial differentiation programs, potentially trapping RGPs in proliferative states.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"17\",\n          \"notes\": \"Ascl1 phosphorylation and microRNA binding influence lineage fate decisions from astrocytes\"\n        },\n        {\n          \"source_id\": \"19\",\n          \"notes\": \"SOX5 suppresses oncogenic PDGFB signaling in gliomas\"\n        },\n        {\n          \"source_id\": \"22\",\n          \"notes\": \"SOX9 and other glial transcription factors control injury-responsive enhancers in astrocytes\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SOX5\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"SOX9\",\n          \"OLIG2\",\n          \"OLIG1\",\n          \"ASCL1\",\n          \"NFI\",\n          \"RFX\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"22\",\n            \"notes\": \"Multiple SOX family members and proneural factors required for complete glial differentiation programs\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Growth Factor Signaling and Neurotrophic Receptor Pathways\",\n      \"description\": \"Genes governing receptor tyrosine kinase signaling, particularly NTRK2 (neurotrophin receptor tyrosine kinase 2) responding to BDNF. This program controls astrocyte proliferation, survival, and differentiation in response to neurotrophic factors. Dysregulation—whether through gene fusion (TRIM24::NTRK2), amplification, or increased ligand availability—drives proliferation through MAPK and PI3K pathway activation, characteristic of astrocytoma.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"BDNF-NTRK2 receptor-mediated signal transduction\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"TRIM24::NTRK2 fusion shows 6-fold increased pTRKB activation; highest activation in PI3K pathway (pAKT 2.9-3.3-fold) and downstream S6 (11.0-13.8-fold)\"\n            },\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"Elevated BDNF in tumor microenvironment increases innervation through TRK2 signaling\"\n            }\n          ],\n          \"genes\": [\n            \"NTRK2\"\n          ]\n        },\n        {\n          \"name\": \"PI3K/AKT and MAPK/ERK signaling cascade activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"AKT1 serine/threonine kinase mutations associated with multiple cancer types; regulates cell survival and proliferation\"\n            },\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"TRIM24::NTRK2 activates pERK, pAKT, pSTAT mediators and downstream S6 phosphorylation\"\n            }\n          ],\n          \"genes\": [\n            \"NTRK2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"NTRK2 receptor and associated signaling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"TRIM24::NTRK2 fusion contains intact tyrosine kinase domain enabling constitutive signaling\"\n            }\n          ],\n          \"genes\": [\n            \"NTRK2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced astrocyte proliferation through MAPK pathway activation\",\n        \"Increased cell survival through PI3K/AKT pathway signaling\",\n        \"Altered metabolic state toward anabolic (growth-promoting) pathways\",\n        \"Dysregulated response to developmental BDNF signals in tumor microenvironment\",\n        \"Potential acquisition of pro-invasive phenotypes through STAT3 activation\"\n      ],\n      \"evidence_summary\": \"NTRK2 encodes the high-affinity receptor for brain-derived neurotrophic factor and mediates neuronal survival, growth, and synaptic plasticity. Recent comprehensive characterization of pediatric high-grade gliomas identifies TRIM24::NTRK2 fusion as a recurring oncogenic driver in diffuse intrinsic pontine gliomas and other pediatric CNS tumors. The fusion protein shows constitutive activation (6-fold increased pTRKB), with highest activation of downstream PI3K pathway (pAKT 2.9-3.3-fold) and MAPK/PI3K mediator S6 (11.0-13.8-fold). Over tumor progression, cells become less reliant on TRIM24::NTRK2 while upregulating additional tyrosine kinases (FGFR1-3, FLT1, KIT, MET), demonstrating both initial NTRK2 dependency and subsequent plasticity. Elevated BDNF in tumor microenvironment increases peripheral innervation, suggesting active role of BDNF-NTRK2 signaling in tumor-host interactions.\",\n      \"significance_score\": 0.89,\n      \"citations\": [\n        {\n          \"source_id\": \"11\",\n          \"notes\": \"TRIM24::NTRK2 fusion demonstrates constitutive tyrosine kinase activation in pediatric gliomas\"\n        },\n        {\n          \"source_id\": \"29\",\n          \"notes\": \"Elevated BDNF in tumor microenvironment mediates innervation through TRK2\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"NTRK2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"BDNF\",\n          \"AKT1\",\n          \"PIK3CA\",\n          \"MAP2K1\",\n          \"MAPK1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"11\",\n            \"notes\": \"AKT and MAPK pathway components downstream of NTRK2\"\n          },\n          {\n            \"source_id\": \"29\",\n            \"notes\": \"BDNF required for NTRK2 signaling activation\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cell Cycle Checkpoint Control and Tumor Suppression\",\n      \"description\": \"Genes governing G1/S and G2/M cell cycle checkpoint control, DNA damage response, and apoptosis induction. TP63 (p63 protein) represents a p53 family member implicated in cell identity and differentiation. WEE1 (G2 checkpoint kinase) phosphorylates CDK1 to prevent premature mitotic entry. Dysregulation—particularly through TP53 loss and WEE1 downregulation—permits uncontrolled cell cycle progression characteristic of astrocytoma.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"G2/M checkpoint control and CDK1 regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"Knockdown of VIM-AS1 increases cell apoptosis via modulation of WEE1 targeting; WEE1 regulates G2 checkpoint through CDK1 phosphorylation\"\n            }\n          ],\n          \"genes\": [\n            \"TP63\"\n          ]\n        },\n        {\n          \"name\": \"DNA damage response and apoptosis induction\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"TP53 R175H mutation shows loss of TP53 function and chromosomal instability; promotes tumor cell invasion\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"TP53 R213X truncation creates premature termination codon; reported in Li-Fraumeni syndrome\"\n            }\n          ],\n          \"genes\": [\n            \"TP63\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"TP53/p63 protein complex and transcriptional regulatory network\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"TP53 mutations at hotspot codons including 175 in DNA binding domain\"\n            }\n          ],\n          \"genes\": [\n            \"TP63\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced cell cycle progression through G2/M checkpoint disruption\",\n        \"Impaired DNA damage response and apoptosis evasion\",\n        \"Acquisition of chromosomal instability and genomic complexity\",\n        \"Disrupted developmental differentiation programs controlled by p63 family members\",\n        \"Increased tumor cell invasiveness through loss of epithelial differentiation constraints\"\n      ],\n      \"evidence_summary\": \"TP63 encodes p63, a p53-related transcription factor implicated in epithelial cell identity and differentiation. The cohort includes TP63 (though TP53 itself is not in the list, TP53 mutations are critical context for astrocytoma). TP53 represents the most frequently mutated gene in astrocytomas, with mutations impairing tumor suppressor function while acquiring gain-of-function properties. The R175H hotspot mutation in TP53 DNA-binding domain results in loss of wild-type tumor suppressor function plus enhanced cell migration and invasion through aberrant transcriptional activation. WEE1 (not directly in list but functionally related to cell cycle programs) phosphorylates CDK1 to maintain G2 arrest, preventing mitotic entry with damaged DNA. Knockdown of WEE1-targeting lncRNAs impairs checkpoint control, allowing cells with unrepaired DNA to enter mitosis. In astrocytoma, loss of TP53 combined with dysregulation of WEE1 and checkpoint control enables uncontrolled proliferation despite genomic damage.\",\n      \"significance_score\": 0.84,\n      \"citations\": [\n        {\n          \"source_id\": \"12\",\n          \"notes\": \"TP53 R175H mutation represents hotspot with loss of function and gain of function properties\"\n        },\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"TP53 R213X nonsense mutation reported in Li-Fraumeni syndrome\"\n        },\n        {\n          \"source_id\": \"48\",\n          \"notes\": \"WEE1 regulation through lncRNA-miRNA interactions controls G2 checkpoint\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"TP63\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"TP53\",\n          \"WEE1\",\n          \"CDK1\",\n          \"CHEK2\",\n          \"ATM\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"12\",\n            \"notes\": \"TP53 and checkpoint kinases essential for cell cycle control\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Reprogramming and Glycolytic-to-Oxidative Metabolism Switching\",\n      \"description\": \"Genes regulating metabolic state, particularly controlling glycolytic versus oxidative phosphorylation balance. SUCLG2 participates in citric acid cycle and lactate metabolism. This program enables the Warburg effect characteristic of astrocytomas—preferential glycolysis generating lactate that accumulates in tumor microenvironment. Dysregulation supports tumor cell proliferation under glucose limitation and shapes immune cell polarization in the tumor microenvironment.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Lactate metabolism and glycolytic reprogramming\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"SUCLG2 knockdown in GBM reduces lactate concentrations; lactate at 10-15 mM significantly reverses viability loss under low-glucose conditions\"\n            }\n          ],\n          \"genes\": [\n            \"SUCLG2\"\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial oxidative phosphorylation and ATP production\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"SUCLG2 knockdown decreases basal and maximal mitochondrial respiratory capacity; decreased ATP production\"\n            }\n          ],\n          \"genes\": [\n            \"SUCLG2\"\n          ]\n        },\n        {\n          \"name\": \"Hypoxia-inducible factor signaling and metabolic adaptation\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"HIF-1α facilitates glucose uptake and lactate production by binding to glycolysis-related genes (Glut1, HK2, LDHA, PKM2)\"\n            }\n          ],\n          \"genes\": [\n            \"SUCLG2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Mitochondrial citric acid cycle enzymes and electron transport chain\",\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"SUCLG2 participates in citric acid cycle; knockdown affects oxidative phosphorylation complex proteins (SDHB, ND1, ATP5A)\"\n            }\n          ],\n          \"genes\": [\n            \"SUCLG2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced glycolytic metabolism and lactate production characteristic of Warburg effect\",\n        \"Tumor cell survival under glucose-limited microenvironmental conditions through lactate utilization\",\n        \"Altered immune cell polarization through lactate-mediated signaling on macrophages\",\n        \"Reduced dependence on oxidative phosphorylation despite metabolic inefficiency\",\n        \"Microenvironmental lactate accumulation reshaping tumor ecosystem\"\n      ],\n      \"evidence_summary\": \"SUCLG2 encodes succinyl-CoA ligase, an enzyme functioning in both the citric acid cycle and fatty acid metabolism. Recent comprehensive analysis demonstrates that SUCLG2 plays a crucial role in regulating lactate metabolism in glioblastoma. SUCLG2 knockdown in glioblastoma cells significantly reduced lactate concentrations within tumor tissue, decreased mitochondrial membrane potential, and reduced proliferation. SUCLG2 knockdown cells showed decreased basal and maximal mitochondrial respiratory capacity with decreased ATP production, accompanied by enhanced glycolytic and glycolytic reserve capacities. Lactate at concentrations of 10-15 mM (achieved in tumor microenvironments) significantly reverses cell viability loss under low-glucose conditions, indicating lactate's critical role in tumor survival. HIF-1α facilitates glucose uptake and lactate production through binding to glycolytic enzyme genes including Glut1, HK2, LDHA, and PKM2. In astrocytoma, dysregulation of SUCLG2 and related metabolic genes promotes glycolytic reprogramming supporting both tumor cell proliferation and immunosuppressive microenvironment effects.\",\n      \"significance_score\": 0.81,\n      \"citations\": [\n        {\n          \"source_id\": \"44\",\n          \"notes\": \"SUCLG2 regulates lactate metabolism and mitochondrial function in GBM; knockdown reduces lactate and inhibits proliferation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SUCLG2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"HIF1A\",\n          \"LDHA\",\n          \"GLUT1\",\n          \"HK2\",\n          \"PKM2\",\n          \"MCT1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"44\",\n            \"notes\": \"Glycolytic enzymes and HIF-1α target genes required for lactate metabolism reprogramming\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Long Non-Coding RNA Regulation of Cancer Phenotypes\",\n      \"description\": \"Genes encoding long non-coding RNAs (lncRNAs) that regulate cancer metabolism, cell proliferation, differentiation, and checkpoint control. The cohort includes multiple LINC genes (large intergenic non-coding RNAs) and lncRNA-associated genes. These transcripts modulate microRNA activity, chromatin accessibility, and signaling pathway engagement to shape astrocytoma phenotypes. Dysregulation of lncRNAs can simultaneously affect metabolic state, proliferation capacity, and drug resistance.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"MicroRNA-mediated post-transcriptional gene silencing\",\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"microRNA-mediated neuronal detargeting through inclusion of miRNA binding sites in transcripts alters lineage trajectories\"\n            },\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"lncRNAs act as competing endogenous RNAs (ceRNAs), sequestering microRNAs and modulating target gene expression\"\n            }\n          ],\n          \"genes\": [\n            \"RMST\",\n            \"LINC00271\",\n            \"LINC00609\",\n            \"LINC00880\",\n            \"LINC00894\",\n            \"LINC01088\",\n            \"LINC01091\",\n            \"LINC01094\",\n            \"LINC01602\",\n            \"LINC02018\",\n            \"LINC02055\"\n          ]\n        },\n        {\n          \"name\": \"Glycolytic reprogramming and metabolic enzyme regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"lncRNAs are critical regulators of cancer metabolism through modulation of glycolytic enzymes and signaling pathways\"\n            }\n          ],\n          \"genes\": [\n            \"RMST\",\n            \"LINC00271\",\n            \"LINC00609\",\n            \"LINC00880\",\n            \"LINC00894\",\n            \"LINC01088\",\n            \"LINC01091\",\n            \"LINC01094\",\n            \"LINC01602\",\n            \"LINC02018\",\n            \"LINC02055\"\n          ]\n        },\n        {\n          \"name\": \"Transcription factor and chromatin accessibility modulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"lncRNAs influence transcription factor activity and chromatin accessibility at target loci\"\n            }\n          ],\n          \"genes\": [\n            \"RMST\",\n            \"LINC00271\",\n            \"LINC00609\",\n            \"LINC00880\",\n            \"LINC00894\",\n            \"LINC01088\",\n            \"LINC01091\",\n            \"LINC01094\",\n            \"LINC01602\",\n            \"LINC02018\",\n            \"LINC02055\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"lncRNA-microRNA-mRNA regulatory networks\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"lncRNAs function as competing endogenous RNAs modulating microRNA activity\"\n            }\n          ],\n          \"genes\": [\n            \"RMST\",\n            \"LINC00271\",\n            \"LINC00609\",\n            \"LINC00880\",\n            \"LINC00894\",\n            \"LINC01088\",\n            \"LINC01091\",\n            \"LINC01094\",\n            \"LINC01602\",\n            \"LINC02018\",\n            \"LINC02055\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced metabolic reprogramming through lncRNA-mediated glycolytic enzyme regulation\",\n        \"Dysregulated cell proliferation and differentiation through miRNA sequestration\",\n        \"Impaired checkpoint control through lncRNA-mediated modulation of WEE1 and related genes\",\n        \"Enhanced drug resistance through lncRNA-dependent chemotherapy response pathways\",\n        \"Altered tumor microenvironment composition through lncRNA-dependent immune signaling\"\n      ],\n      \"evidence_summary\": \"The cohort includes multiple long non-coding RNA genes (RMST, LINC00271, LINC00609, LINC00880, LINC00894, LINC01088, LINC01091, LINC01094, LINC01602, LINC02018, LINC02055) that regulate cancer biology. Recent comprehensive review identifies lncRNAs as critical regulators of cancer metabolism, particularly in glycolytic reprogramming supporting tumor growth. lncRNAs influence metabolic adaptation by modulating glycolytic enzymes, transcription factors, and signaling pathways. VIM-AS1 (vimentin antisense RNA) exemplifies lncRNA function: its knockdown inhibits glioma cell proliferation and migration while increasing apoptosis through modulation of WEE1 targeting. lncRNAs also function as competing endogenous RNAs (ceRNAs), sequestering microRNAs and thereby modulating target mRNA expression and protein synthesis. These multifaceted regulatory mechanisms position lncRNAs as both mechanistic drivers and therapeutic targets in astrocytoma, with potential for personalized lncRNA-targeted therapies.\",\n      \"significance_score\": 0.79,\n      \"citations\": [\n        {\n          \"source_id\": \"47\",\n          \"notes\": \"lncRNAs regulate cancer metabolism through glycolytic enzyme and transcription factor modulation\"\n        },\n        {\n          \"source_id\": \"48\",\n          \"notes\": \"VIM-AS1 lncRNA modulates WEE1 to control cell proliferation and checkpoint function in gliomas\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"RMST\",\n        \"LINC00271\",\n        \"LINC00609\",\n        \"LINC00880\",\n        \"LINC00894\",\n        \"LINC01088\",\n        \"LINC01091\",\n        \"LINC01094\",\n        \"LINC01602\",\n        \"LINC02018\",\n        \"LINC02055\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"DICER1\",\n          \"DROSHA\",\n          \"AGO2\",\n          \"LIN28\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"47\",\n            \"notes\": \"microRNA processing and RISC machinery required for lncRNA-miRNA-mRNA regulatory networks\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Astrocyte Activation and Reactive Gliosis Program\",\n      \"description\": \"Genes controlling astrocyte activation responses, including acute pro-inflammatory, subacute transitional, and chronic neurodegenerative states. This program orchestrates how astrocytes respond to injury, infection, or tumor-associated signals. In astrocytoma contexts, dysregulation of astrocyte activation programs could either promote tumor progression (through immunosuppression and altered metabolic support) or impair anti-tumor responses (through loss of normal homeostatic astrocyte functions).\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Pro-inflammatory transcriptional activation and cytokine production\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"Acute astrocyte activation features pro-inflammatory transcriptome with upregulation of TNF, IL-1β, IL-17rc, Ccl2, Cxcl10 and immediate early genes Junb, Egr1\"\n            }\n          ],\n          \"genes\": []\n        },\n        {\n          \"name\": \"Transition from inflammation to neurodegeneration\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"Subacute phase shows persistent low-level pro-inflammatory signaling; upregulation of regulatory and homeostatic pathways\"\n            }\n          ],\n          \"genes\": []\n        },\n        {\n          \"name\": \"Synaptic pruning and neuronal apoptotic pathways\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"Subacute and chronic phases feature upregulation of synapse pruning mediators (Sparc, Mertk, C1q) and neuronal apoptotic pathways\"\n            }\n          ],\n          \"genes\": []\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Astrocytic activation state-specific gene expression signatures\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"Distinct transcriptional signatures associated with A1-like (pro-inflammatory) and A2-like (pro-healing) astrocyte states\"\n            }\n          ],\n          \"genes\": []\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Altered astrocyte contribution to tumor microenvironment through dysregulated activation states\",\n        \"Enhanced or impaired pro-inflammatory responses affecting immune cell recruitment\",\n        \"Disrupted neuroprotective astrocytic functions in chronic tumor settings\",\n        \"Potential locking of tumor-associated astrocytes in particular activation states\",\n        \"Altered metabolic support to tumor cells through activation state-dependent metabolite provision\"\n      ],\n      \"evidence_summary\": \"Recent comprehensive RNA-sequencing of astrocytes isolated at acute, subacute, and chronic timepoints following traumatic brain injury reveals dynamically evolving astrocyte transcriptomes. Acute activation (2 days post-injury) features a distinct pro-inflammatory signature with 2,588 differentially regulated transcripts (P adj < 0.05). Upregulated genes include pro-inflammatory cytokines (TNF, IL-1β, IL-17rc), chemokines (CCL2, CXCL10), and immediate early genes (Junb, Egr1). At 2 weeks (subacute phase), most acute inflammatory genes showed reduced expression while astrocytes upregulated regulatory and homeostatic pathways including synaptic regulation, axonogenesis, and neuronal stem cell maintenance. Chronic-phase astrocytes (1 year post-injury) maintained low-level pro-inflammatory signaling but prominently upregulated neurodegenerative pathways including mitochondrial and neuronal apoptotic pathways. Notably, chronic-phase astrocytes showed increased Ndrg1 (highly expressed in brain tumors including astrocytoma and glioblastoma) and decreased Rbpj (whose deletion promotes neurogenesis), suggesting persistent stress and aberrant activation. While this program is insufficiently represented by genes from the input list, understanding astrocyte activation dynamics is critical to comprehending how astrocytomas co-opt or dysregulate normal astrocytic responses.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"39\",\n          \"notes\": \"Comprehensive RNA-seq of astrocytes reveals dynamically evolving activation states from acute to chronic phases\"\n        }\n      ],\n      \"supporting_genes\": [],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"TNF\",\n          \"IL1B\",\n          \"IL17RC\",\n          \"CCL2\",\n          \"CXCL10\",\n          \"GFAP\",\n          \"VIM\",\n          \"S100B\",\n          \"AQP4\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"39\",\n            \"notes\": \"Multiple inflammatory cytokines, chemokines, and astrocytic markers essential for characterizing activation states\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cell Adhesion and Extracellular Matrix Interactions\",\n      \"description\": \"Genes governing cell adhesion, extracellular matrix composition, and cellular interactions within the tumor microenvironment. This program determines how astrocytic tumor cells interface with pericytes, endothelial cells, immune cells, and the surrounding ECM. Dysregulation alters invasion, angiogenesis, immune suppression, and blood-brain barrier integrity characteristic of astrocytoma.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Cell-cell adhesion and contact-dependent signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Pericyte-astrocyte interactions dampen immune cell polarization; pericyte depletion results in increased abundance of immune-suppressive macrophages\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Pericytes orchestrate tumor-restraining microenvironment; depletion accelerates tumor progression\"\n            }\n          ],\n          \"genes\": [\n            \"PLEKHA5\",\n            \"PLEKHA7\",\n            \"PTPRQ\"\n          ]\n        },\n        {\n          \"name\": \"Extracellular matrix composition and remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"Spatial transcriptomics reveals nearly 400 ECM genes dysregulated in GBM; differential ECM expression in vascular endothelial cells and microglia/macrophages\"\n            }\n          ],\n          \"genes\": [\n            \"PLEKHA5\",\n            \"PLEKHA7\",\n            \"PTPRQ\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Cell adhesion molecule complexes and focal adhesions\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Pericyte-endothelial cell interactions altered by pericyte depletion; dysregulated vessel growth and BBB integrity\"\n            }\n          ],\n          \"genes\": [\n            \"PLEKHA5\",\n            \"PLEKHA7\",\n            \"PTPRQ\"\n          ]\n        },\n        {\n          \"name\": \"Extracellular matrix protein networks and spatial organization\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"Spatial heterogeneity in ECM composition creates distinct tumor microenvironmental niches\"\n            }\n          ],\n          \"genes\": [\n            \"PLEKHA5\",\n            \"PLEKHA7\",\n            \"PTPRQ\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated tumor-stromal interactions affecting pericyte coverage and blood-brain barrier integrity\",\n        \"Enhanced tumor cell invasion through altered ECM signaling\",\n        \"Increased immune suppression through altered pericyte-immune cell interactions\",\n        \"Enhanced angiogenesis and abnormal vasculature characteristic of astrocytoma\",\n        \"Altered spatial organization of tumor microenvironment into distinct niches\"\n      ],\n      \"evidence_summary\": \"The cohort includes genes encoding adhesion molecules and ECM-interacting proteins (PLEKHA5, PLEKHA7 encoding pleckstrin homology domain containing proteins; PTPRQ encoding protein tyrosine phosphatase receptor Q). Recent spatial transcriptomic studies reveal that glioblastomas contain nearly 400 differentially expressed ECM genes compared to normal brain, with distinct expression patterns in different tumor cell populations and stromal cells. Vascular endothelial cells and microglia/macrophages show largely non-overlapping ECM expression signatures, creating spatially distinct microenvironmental niches. Critically, pericytes orchestrate tumor-restraining microenvironments: pericyte depletion through genetic engineering results in both accelerated tumor progression and significantly shortened survival. Pericyte-deficient tumors show dysregulated vessel growth, reduced blood-brain barrier patency, increased tumor cell vessel co-option, altered endothelial cell signaling, and increased abundance of immune-suppressive macrophages expressing IL4-induced markers (Retnla, Ccl24, Mrc1, Arg1, Klf4). This demonstrates that ECM-mediated interactions between tumor cells and stromal components fundamentally shape astrocytoma progression.\",\n      \"significance_score\": 0.76,\n      \"citations\": [\n        {\n          \"source_id\": \"24\",\n          \"notes\": \"Pericytes suppress immune polarization toward suppressive phenotypes; depletion accelerates tumor progression\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"Pericyte depletion results in dysregulated vasculature and increased immune suppression\"\n        },\n        {\n          \"source_id\": \"42\",\n          \"notes\": \"Spatial transcriptomics reveals ECM heterogeneity and distinct stromal-tumor niches\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"PLEKHA5\",\n        \"PLEKHA7\",\n        \"PTPRQ\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CDH1\",\n          \"CDH2\",\n          \"ICAM1\",\n          \"NCAM1\",\n          \"LAMININ\",\n          \"COLLAGEN\",\n          \"FIBRONECTIN\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"42\",\n            \"notes\": \"Classical cell adhesion molecules and ECM proteins required for microenvironment interactions\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Developmental Plasticity and Multicellular Progenitor Fate Specification\",\n      \"description\": \"An integrative meta-program unifying the centrosome asymmetry, endosomal trafficking, microtubule organization, transcriptional control, and ciliary signaling programs described above. This program collectively determines whether RGPs self-renew symmetrically or undergo asymmetric division producing differentiated progeny. In normal development, this program maintains developmental plasticity while constraining proliferation. In astrocytoma, dysregulation unlocks proliferative potential while eliminating differentiation constraints, driving malignant transformation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Asymmetric cell division and progenitor-differentiation fate specification\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"PCM1-mediated centrosome asymmetry controls RGP division mode distribution (P/P vs. P/N vs. N/N); loss of pcm1 increases N/N divisions from 19% to 49%\"\n            },\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"Injury-responsive enhancers govern glial cell transcriptional reprogramming; unique and shared programs in different glial types\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC30\",\n            \"CCDC40\",\n            \"CCDC146\",\n            \"CCDC170\",\n            \"PARD3B\",\n            \"DYNLRB2\",\n            \"SOX5\",\n            \"TUBA1A\",\n            \"TTLL9\",\n            \"PACRG\"\n          ]\n        },\n        {\n          \"name\": \"Developmental signal integration through primary cilia\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"Primary cilia seed by mother centrosome; ciliary dynamics regulate developmental signal reception\"\n            },\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"Ciliary activities essential for polarized radial glial scaffold formation\"\n            }\n          ],\n          \"genes\": [\n            \"DNAH5\",\n            \"DNAH6\",\n            \"DNAH7\",\n            \"DNAH9\",\n            \"DNAH11\",\n            \"DNAH12\",\n            \"DNAI1\",\n            \"DNAAF1\",\n            \"ROPN1L\",\n            \"DRC1\",\n            \"DRC7\",\n            \"CFAP46\",\n            \"CFAP47\",\n            \"CFAP52\",\n            \"CFAP54\",\n            \"CFAP57\",\n            \"CFAP61\"\n          ]\n        },\n        {\n          \"name\": \"Developmental timing and cell cycle pace setting\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"DNA replication fork speed acts as pacer controlling developmental timing in cortical neurogenesis\"\n            }\n          ],\n          \"genes\": [\n            \"TUBA1A\",\n            \"TTLL9\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Integrated asymmetric cell division apparatus\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"PCM1-Par-3 complexes on Dld endosomes; asymmetric microtubule organization around centrosomes; differential centrosome inheritance\"\n            }\n          ],\n          \"genes\": [\n            \"CCDC30\",\n            \"CCDC40\",\n            \"CCDC146\",\n            \"CCDC170\",\n            \"PARD3B\",\n            \"DYNLRB2\",\n            \"TUBA1A\",\n            \"TTLL9\",\n            \"PACRG\"\n          ]\n        },\n        {\n          \"name\": \"Developmental signal transduction complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"Injury-responsive enhancers contain binding sites for lineage-specific and stimulus-induced transcription factors\"\n            }\n          ],\n          \"genes\": [\n            \"SOX5\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Fundamental alteration of RGP proliferative capacity and differentiation potential\",\n        \"Loss of developmental constraints normally limiting progenitor expansion\",\n        \"Acquisition of symmetric self-renewing phenotype characteristic of cancer stem cells\",\n        \"Enhanced susceptibility to oncogenic transformation through loss of developmental plasticity controls\",\n        \"Potential acquisition of multipotent progenitor characteristics in tumor cells\",\n        \"Disrupted developmental timing creating temporal dysregulation of proliferation and differentiation\"\n      ],\n      \"evidence_summary\": \"The collective evidence from multiple interconnected programs demonstrates that developmental plasticity in radial glia progenitors depends on proper functioning of an integrated system including centrosome asymmetry (PCM1, CCDC proteins), endosomal trafficking (PARD3B, DYNLRB2), microtubule organization (TUBA1A, TTLL9, PACRG), ciliary signaling (DNAH, DNAI, radial spoke proteins), and transcriptional control (SOX5). Loss or dysregulation of multiple components simultaneously would fundamentally alter RGP biology, potentially unlocking proliferative potential while simultaneously eliminating developmental constraints that normally drive differentiation. The evidence that pcm1 loss increases differentiating divisions (N/N) suggests that acute loss of centrosome asymmetry programs initially promotes differentiation. However, if such dysregulation occurs in RGPs that have simultaneously acquired TP53 loss or other oncogenic mutations preventing differentiation, the result would be proliferation-prone cells resistant to developmental signals—precisely the phenotype of astrocytoma. This integrative program likely represents the fundamental developmental plasticity mechanism that becomes dysregulated during astrocytoma initiation and that astrocytomas retain to enable adaptive plasticity during progression.\",\n      \"significance_score\": 0.93,\n      \"citations\": [\n        {\n          \"source_id\": \"33\",\n          \"notes\": \"PCM1 integrates centrosome asymmetry with endosomal trafficking and cell fate specification in RGPs\"\n        },\n        {\n          \"source_id\": \"22\",\n          \"notes\": \"Injury-responsive enhancers coordinate glial cell transcriptional programs reflecting cell-type identity\"\n        },\n        {\n          \"source_id\": \"36\",\n          \"notes\": \"DNA replication dynamics pace developmental timing in cortical development\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CCDC30\",\n        \"CCDC40\",\n        \"CCDC146\",\n        \"CCDC170\",\n        \"PARD3B\",\n        \"DYNLRB2\",\n        \"DNAH5\",\n        \"DNAH6\",\n        \"DNAH7\",\n        \"DNAH9\",\n        \"DNAH11\",\n        \"DNAH12\",\n        \"DNAI1\",\n        \"DNAAF1\",\n        \"ROPN1L\",\n        \"DRC1\",\n        \"DRC7\",\n        \"CFAP46\",\n        \"CFAP47\",\n        \"CFAP52\",\n        \"CFAP54\",\n        \"CFAP57\",\n        \"CFAP61\",\n        \"SOX5\",\n        \"TUBA1A\",\n        \"TTLL9\",\n        \"PACRG\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"NOTCH1\",\n          \"JAG1\",\n          \"DLL1\",\n          \"HES1\",\n          \"NGN2\",\n          \"BDNF\",\n          \"GDNF\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"22\",\n            \"notes\": \"Notch signaling and developmental neurotrophic factors required for complete developmental plasticity control\"\n          },\n          {\n            \"source_id\": \"36\",\n            \"notes\": \"Multiple developmental signaling pathways coordinate timing and fate specification\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Gene ontology and functional annotation from primary literature\",\n      \"Protein-protein interaction networks inferred from pathway databases\",\n      \"Co-citation analysis linking genes through shared biological processes\",\n      \"Developmental biology and neuroscience literature on radial glia progenitors and astrocytes\",\n      \"Cancer genomics literature on astrocytoma molecular alterations\",\n      \"Systems-level analysis of programs regulating cell fate and proliferation\"\n    ],\n    \"notes\": \"Analysis prioritized well-established functions with strong literature support, particularly focusing on centrosomal and ciliary biology in developmental contexts, transcriptional control of glial fate decisions, and metabolic reprogramming in gliomas. Emerging evidence from recent spatial transcriptomics and single-cell studies informed interpretation of microenvironmental interactions and tumor heterogeneity. Integration of normal developmental processes with disease-specific alterations enabled identification of dysregulated programs likely contributing to astrocytoma initiation and progression.\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n---\n\n## Discussion of Gene Program Dysregulation in Astrocytoma Context\n\nThe comprehensive analysis identifies twelve major gene programs with significant relevance to astrocytoma biology. These programs do not function independently but rather form an integrated developmental and cellular regulation system. Dysregulation of multiple programs simultaneously likely drives astrocytoma transformation and progression, whereas dysregulation of individual programs might produce more limited phenotypic consequences.\n\nThe highest-ranked programs (significance scores 0.88-0.93) include the **Primary Ciliary Axonemal Dyneins and Motor Apparatus** program, the **Centrosome Asymmetry and Asymmetric Cell Division Control** program, and the integrative **Developmental Plasticity and Multicellular Progenitor Fate Specification** meta-program. These programs collectively govern whether radial glia progenitors maintain developmental plasticity and respond to developmental differentiation signals or become locked in proliferative states resistant to differentiation cues.\n\nThe **Transcriptional Control of Glial Differentiation and Neurogenic Fate** program (score 0.85) and the **Growth Factor Signaling and Neurotrophic Receptor Pathways** program (score 0.89) directly control whether astrocytic progenitors differentiate or maintain proliferative potential. Dysregulation of SOX5, a key member of the transcriptional program, suppresses oncogenic signaling during normal glioma development, suggesting that SOX5 loss contributes to tumorigenesis.\n\nThe **Metabolic Reprogramming and Glycolytic-to-Oxidative Metabolism Switching** program (score 0.81) and the **Long Non-Coding RNA Regulation of Cancer Phenotypes** program (score 0.79) enable the fundamental metabolic and transcriptional alterations characterizing astrocytoma, supporting both tumor cell proliferation and immunosuppressive microenvironment effects.\n\nA critical finding is that dysregulation of any single program likely has limited transformative capacity, but simultaneous dysregulation of multiple programs creates a synergistic effect. For instance, loss of ciliary function (through dynein dysregulation) impairs developmental signal reception, but this might initially increase differentiation unless simultaneously coupled with mutations preventing differentiation (such as TP53 loss). Dysregulation of transcriptional programs that promote proliferation (through loss of SOX5 tumor-suppressive function) combined with loss of differentiation signals (through ciliary dysfunction) would create particularly permissive conditions for astrocytoma initiation and progression.\n\nThe analysis highlights that genes in the provided cohort likely evolved under selective pressure to maintain developmental plasticity while constraining proliferation—functions that become precisely the opposite when dysregulated in tumor contexts. Understanding these programs at molecular, cellular, and systems levels offers opportunities for identifying patient subgroups based on specific program dysregulation patterns and for designing therapeutically targeted interventions addressing particular dysregulated programs rather than single genes.",
    "citations": [
      "https://www.ncbi.nlm.nih.gov/gene/2697",
      "https://www.ncbi.nlm.nih.gov/gene/207",
      "https://www.ncbi.nlm.nih.gov/gene/627",
      "https://www.ncbi.nlm.nih.gov/gene/4763",
      "https://www.ncbi.nlm.nih.gov/gene/5817",
      "https://www.ncbi.nlm.nih.gov/gene/5133",
      "https://www.ncbi.nlm.nih.gov/gene/3832",
      "https://www.ncbi.nlm.nih.gov/gene/1499",
      "https://www.ncbi.nlm.nih.gov/gene/4867",
      "https://www.ncbi.nlm.nih.gov/gene/80184",
      "https://www.nature.com/articles/s41698-025-01190-3",
      "https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000012374",
      "https://pubmed.ncbi.nlm.nih.gov/41308678/",
      "https://www.ncbi.nlm.nih.gov/gene/7015",
      "https://www.ncbi.nlm.nih.gov/clinvar/variation/43590/",
      "https://pubmed.ncbi.nlm.nih.gov/41373636/?fc=None&ff=20251211105245&v=2.18.0.post22+67771e2",
      "https://www.nature.com/articles/s42003-025-09169-3",
      "https://www.ncbi.nlm.nih.gov/gene/7161",
      "https://www.ncbi.nlm.nih.gov/gene/6660",
      "https://www.ncbi.nlm.nih.gov/gene/4582",
      "https://www.nature.com/articles/s41467-025-66708-6",
      "https://www.nature.com/articles/s41593-025-02131-w",
      "https://www.ncbi.nlm.nih.gov/gene/3064",
      "https://www.nature.com/articles/s41467-025-66985-1",
      "https://www.nature.com/articles/s41467-025-65933-3",
      "https://www.ncbi.nlm.nih.gov/gene/6103",
      "https://www.ncbi.nlm.nih.gov/gene/4804",
      "https://www.ncbi.nlm.nih.gov/gene/57096",
      "https://www.ncbi.nlm.nih.gov/gene/24842",
      "https://www.ncbi.nlm.nih.gov/gene/12803",
      "https://www.nature.com/articles/s41467-025-65756-2",
      "https://www.ncbi.nlm.nih.gov/gene/1270",
      "https://www.nature.com/articles/s41467-025-65269-y",
      "https://www.ncbi.nlm.nih.gov/gene/4313",
      "https://www.nature.com/articles/s42003-025-09138-w",
      "https://www.nature.com/articles/s42003-025-09270-7",
      "https://pubmed.ncbi.nlm.nih.gov/41248289/",
      "https://www.nature.com/articles/s41420-025-02856-4",
      "https://www.ncbi.nlm.nih.gov/gene/991",
      "https://www.nature.com/articles/s41598-025-30291-z",
      "https://www.nature.com/articles/s41419-025-08289-2",
      "https://www.ncbi.nlm.nih.gov/gene/7465",
      "https://www.nature.com/articles/s41598-025-30291-z_reference.pdf",
      "http://json-schema.org/draft-07/schema#\","
    ],
    "duration_seconds": null
  }
}